ReviewEuropean clinical respiratory journal2021
Fractional exhaled nitric oxide as a determinant for the clinical course of asthma: a systematic review.
Review in European clinical respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Chinese Expert Consensus on the Testing Process, Quality Control and Clinical Application of Fractional Exhaled Nitric Oxide (2025).The clinical respiratory journal · 2026Article
- Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
- Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.Journal of inflammation research · 2026Review
- Fractional exhaled nitric oxide (FeNO) in chronic obstructive respiratory diseases is associated with the bronchodilator response.Journal of thoracic disease · 2025Article
- Article
- Pulmonary Rehabilitation Reduces Airway Inflammation in Asthma Patients with High FeJournal of asthma and allergy · 2025Article
- Relationship between fraction of exhaled nitric oxide and peripheral eosinophilia in asthma.Annals of medicine · 2024Article
- NO Casting of NETs in Allergic Asthma.American journal of respiratory and critical care medicine · 2024Article
- Prediction of Asthma Exacerbations in Children.Journal of personalized medicine · 2023Review
- Update on the Role of FeNO in Asthma Management.Diagnostics (Basel, Switzerland) · 2023Review
- Can the Chinese study on the normal range of FeNO in children evaluate standardized asthma treatment efficacy in 6- to 12-year-old children?Frontiers in pediatrics · 2023Article
- Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.Frontiers in immunology · 2023Article
- Breath Tests Used in the Context of Bariatric Surgery.Diagnostics (Basel, Switzerland) · 2022Review
- Severe asthma treatment patterns: A multicenter observational study in the Gulf region.The World Allergy Organization journal · 2022Article
- Understanding the Cellular Sources of the Fractional Exhaled Nitric Oxide (FeNO) and Its Role as a Biomarker of Type 2 Inflammation in Asthma.BioMed research international · 2022Review
- Management of Children with Acute Asthma Attack: A RAND/UCLA Appropriateness Approach.International journal of environmental research and public health · 2021Article
- Uncontrolled Asthma: Unmet Needs in the Management of Patients.Journal of asthma and allergy · 2021Review
- Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis.Journal of asthma and allergy · 2021Article
- [Consensus document for Severe Asthma. 2025 Update].Open respiratory archivesArticle
- SymptomTherapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrecision medicine means linking the right patient to the right management strategy including best possible pharmacological therapy, considering the individual variability of the disease characteristics, type of inflammation, genes, environment, and lifestyle. For heterogenous diseases such as asthma, reliable biomarkers are needed to facilitate the best possible disease control and reduce the risk of side effects. The present review examines fractional exhaled nitric oxide (FeNO) as a guide for the management strategy of asthma and predictor of its clinical course.
methodThe literature included was identified by searching the PubMed database using specific key words and MeSH terms. Studies were not excluded based on their design alone. The search resulted in 212 hits, of which 35 articles were included in this review.
resultsSeveral studies support a potential role for high FeNO levels as a prognostic biomarker for accelerated lung function decline in adults with newly diagnosed asthma. Furthermore, studies report an association between high FeNO levels and excess decline in FEV
conclusionThe present review provides evidence of the prognostic value of FeNO as a surrogate biomarker for type 2 inflammation in the airways. FeNO is likely to emerge as an important biomarker in monitoring and tailoring modern asthma treatment, either alone or in combination with other biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.